Preventive and therapeutic approaches to the newborn infant with perinatal viral and toxoplasma infections.
D000998:Antiviral Agents / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000151:congenital / Q000628:therapy; D006561:Herpes Simplex / Q000151:congenital / Q000628:therapy; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000628:therapy*; D007372:Interferons / Q000627:therapeutic use; D011739:Pyrimethamine / Q000627:therapeutic use; D012409:Rubella / Q000151:congenital / Q000628:therapy; D013411:Sulfadiazine / Q000627:therapeutic use; D014125:Toxoplasmosis, Congenital / Q000628:therapy*; D014611:Vaccination; D014740:Vidarabine / Q000627:therapeutic use; D014765:Viral Vaccines / Q000627:therapeutic use; D014777:Virus Diseases / Q000151:congenital*
D000998:Antiviral Agents; D014765:Viral Vaccines; D013411:Sulfadiazine; D007372:Interferons; D014740:Vidarabine; D011739:Pyrimethamine